Working... Menu

Safety of ALLO-ASC-DFU in the Patients With Diabetic Foot Ulcers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02394886
Recruitment Status : Completed
First Posted : March 20, 2015
Last Update Posted : October 16, 2015
Information provided by (Responsible Party):
Anterogen Co., Ltd.

Brief Summary:
This is a phase I open-label study to evaluate the safety of ALLO-ASC-DFU in diabetic foot ulcers patients. ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide an new option in treating a diabetic foot ulcer.

Condition or disease Intervention/treatment Phase
Diabetic Foot Ulcer Biological: ALLO-ASC-DFU Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 5 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Clinical Study to Evaluate the Safety of ALLO-ASC-DFU in the Patients With Diabetic Foot Ulcers
Study Start Date : November 2014
Actual Primary Completion Date : May 2015
Actual Study Completion Date : July 2015

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: ALLO-ASC-DFU
ALLO-ASC-DFU treatment with conventional care
Biological: ALLO-ASC-DFU

Primary Outcome Measures :
  1. Number of Participants with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: up to 4 weeks ]

Secondary Outcome Measures :
  1. Wound size and depth measurement [ Time Frame: baseline and 1, 2, 4 weeks ]
    Evaluation of the improvement of wound measured by size and depth, and examines the change for 4 weeks period.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Subject is between 18 and 80 years of age.
  2. Subject is diagnosed with Type I or Type II diabetes.
  3. Subjects who have a wound defined as diabetic foot ulcer presence for more than 4 weeks, but not present for more than 54 weeks at the screening visit.
  4. Foot ulcer located below the malleoli on plantar or dorsal surface of the foot and ulcer size is between 1 cm^2 and 25 cm^2.
  5. Ulcer extends into the dermis or subcutaneous tissue without evidence of exposed muscle, tendon, bone, or joint capsule.
  6. Ulcer is free of necrotic debris, exhibits no signs of clinical infection, and appears to be made of primarily vascularized tissue.
  7. 0.7 < Ankle Brachial Index (ABI) < 1.3.
  8. Subject is able to give written informed consent prior to study start and to comply with the study requirements.

Exclusion Criteria:

  1. Ulcer is of non-diabetic pathophysiology.
  2. Gangrene is present on any part of the affected foot.
  3. Ulcer is over an active Charcot deformity.
  4. The ulcer has increased or decreased in size by 30% or more during one week after the screening visit.
  5. The longest dimension of the Index Ulcer exceeds 5 cm at the screening visit.
  6. Subject is Human Immunodeficiency Virus (HIV) positive.
  7. Subjects with severe hepatic deficiencies.
  8. Subjects with a glycated hemoglobin A1c (HbA1c) level of > 12%.
  9. Subject who are allergic or have a hypersensitive reaction to bovine-derived proteins or fibrin glue.
  10. Subjects requiring intravenous (IV) antibiotics to treat the index wound infection.
  11. Subjects who are currently receiving dialysis.
  12. Subjects who are pregnant or breast-feeding.
  13. Subjects who are unwilling to use an "effective" method of contraception during the study.
  14. Current evidence of osteomyelitis, cellulitis, or other evidence of infection including pus drainage from the wound site.
  15. Subjects who have a clinically relevant history of alcohol or drugs abuse.
  16. Subject's blood sugar is > 450 mg/dL at postprandial.
  17. Subjects who are not able to understand the objective of this study or to comply with the study requirements.
  18. Subjects who are considered to have a significant disease which can impact the study by the investigator.
  19. Subjects who are considered not suitable for the study by the investigator.
  20. Subjects who have a history of surgery for malignant tumor within the last five years (except carcinoma site).
  21. Subjects who are currently or were enrolled in another clinical study within 60 days of screening.
  22. Subjects who have undergone wound treatments with growth factors, dermal substitutes, or other biological therapies within the last 30 days.
  23. Subjects who are receiving oral or parenteral corticosteroids, immunosuppressive, or cytotoxic agents.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02394886

Layout table for location information
Korea, Republic of
Asan Medical Center
Seoul, Korea, Republic of
Sponsors and Collaborators
Anterogen Co., Ltd.
Layout table for investigator information
Principal Investigator: Joon Pio Hong, MD, PhD Asan Medical Center

Layout table for additonal information
Responsible Party: Anterogen Co., Ltd. Identifier: NCT02394886     History of Changes
Other Study ID Numbers: ALLO-ASC-DFU-101
First Posted: March 20, 2015    Key Record Dates
Last Update Posted: October 16, 2015
Last Verified: March 2015

Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetic Foot
Foot Ulcer
Pathologic Processes
Diabetic Angiopathies
Vascular Diseases
Cardiovascular Diseases
Leg Ulcer
Skin Ulcer
Skin Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Diabetic Neuropathies
Foot Diseases